| __timestamp | BioMarin Pharmaceutical Inc. | Exelixis, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 50829000 |
| Thursday, January 1, 2015 | 402271000 | 57305000 |
| Friday, January 1, 2016 | 476593000 | 116145000 |
| Sunday, January 1, 2017 | 554336000 | 159362000 |
| Monday, January 1, 2018 | 604353000 | 206366000 |
| Tuesday, January 1, 2019 | 680924000 | 228244000 |
| Wednesday, January 1, 2020 | 737669000 | 293355000 |
| Friday, January 1, 2021 | 759375000 | 401715000 |
| Saturday, January 1, 2022 | 854009000 | 459856000 |
| Sunday, January 1, 2023 | 937300000 | 542705000 |
| Monday, January 1, 2024 | 1009025000 | 492128000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding the financial strategies of leading companies is crucial. Over the past decade, BioMarin Pharmaceutical Inc. and Exelixis, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, BioMarin's SG&A expenses surged by approximately 210%, reflecting a strategic investment in growth and market expansion. In contrast, Exelixis experienced a remarkable 970% increase, indicating a significant scaling of operations and market presence.
BioMarin's steady rise in expenses, peaking at $937 million in 2023, underscores its commitment to maintaining a robust administrative framework. Meanwhile, Exelixis's expenses, reaching $543 million in the same year, highlight its aggressive expansion strategy. These trends offer a window into the operational priorities of these biotech giants, providing valuable insights for investors and industry analysts alike.
Selling, General, and Administrative Costs: Novartis AG vs Exelixis, Inc.
Breaking Down SG&A Expenses: Pfizer Inc. vs Exelixis, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Exelixis, Inc.
SG&A Efficiency Analysis: Comparing Teva Pharmaceutical Industries Limited and Exelixis, Inc.
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: Insmed Incorporated vs BioMarin Pharmaceutical Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Madrigal Pharmaceuticals, Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Vericel Corporation Trends and Insights
BioMarin Pharmaceutical Inc. and Travere Therapeutics, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Exelixis, Inc. and Travere Therapeutics, Inc.